- Home
- PSHG vs LTRN Comparison
PSHG vs LTRN Comparison
Compare PSHG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | LTRN |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 22.2M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSHG | LTRN |
|---|---|---|
| Price | $1.73 | $3.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.8K | ★ 282.8K |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $1.11 |
| 52 Week High | $2.58 | $5.74 |
Technical Indicators
Market Signals| Indicator | PSHG | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 70.09 |
| Support Level | N/A | $3.04 |
| Resistance Level | $2.04 | $3.79 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 10.37 | 88.72 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.